A Physiologically Based Pharmacokinetic Model of Mitoxantrone in Mice and Scale-up to Humans: a Semi-Mechanistic Model Incorporating DNA and Protein Binding-Reference-Cited by-同舟云学术

A Physiologically Based Pharmacokinetic Model of Mitoxantrone in Mice and Scale-up to Humans: a Semi-Mechanistic Model Incorporating DNA and Protein Binding

Published:2012-03-27 Issue:2 Volume:14 Page:352-364
ISSN:1550-7416
Container-title:The AAPS Journal
language:en
Short-container-title:AAPS J

Author:

An Guohua,Morris Marilyn E.

Publisher

Springer Science and Business Media LLC

Subject

Pharmaceutical Science

Link

http://link.springer.com/content/pdf/10.1208/s12248-012-9344-7.pdf

Reference41 articles.

1. Smith IE. Mitoxantrone (novantrone): a review of experimental and early clinical studies. Cancer Treat Rev. 1983;10:103–15.

2. Batra VK, Morrison JA, Woodward DL, Siverd NS, Yacobi A. Pharmacokinetics of mitoxantrone in man and laboratory animals. Drug Metab Rev. 1986;17:311–29.

3. Durr FE, Wallace RE, Citarella RV. Molecular and biochemical pharmacology of mitoxantrone. Cancer Treat Rev. 1983;10(Suppl B):3–11.

4. Young CW, Raymond V. Clinical assessment of the structure-activity relationship of anthracyclines and related synthetic derivatives. Cancer Treat Rep. 1986;70:51–63.

5. Scott LJ, Figgitt DP. Mitoxantrone: a review of its use in multiple sclerosis. CNS Drugs. 2004;18:379–96.

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nanomedicines in diagnosis and treatment of prostate cancers: an updated review;Frontiers in Bioengineering and Biotechnology;2024-08-21

2. A whole-body mechanistic physiologically-based pharmacokinetic modeling of intravenous iron;Drug Delivery and Translational Research;2024-07-24

3. No Interference of H9 Extract on Trastuzumab Pharmacokinetics in Their Combinations;International Journal of Molecular Sciences;2023-11-23

4. Improved Pharmacokinetic Feasibilities of Mirabegron-1,2-Ethanedisulfonic Acid, Mirabegron-1,5-Naphthalenedisulfonic Acid, and Mirabegron-L-Pyroglutamic Acid as Co-Amorphous Dispersions in Rats and Mice;Pharmaceutics;2023-09-04

5. Evaluation of Pharmacokinetic Feasibility of Febuxostat/L-pyroglutamic Acid Cocrystals in Rats and Mice;Pharmaceutics;2023-08-21